Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Autor:
Yusuke Kaida, Naoki Inui, Kazuki Furuhashi, Yusuke Inoue, Tomohiro Uto, Katsuhiro Yoshimura, Kazutaka Mori, Noriyuki Enomoto, Mitsuru Niwa, Hiroyuki Matsuda, Shun Matsuura, Yuzo Suzuki, Yutaro Nakamura, Masato Fujii, Masato Karayama, Hironao Hozumi, Mikio Toyoshima, Yasuhiro Ito, Takafumi Suda, Dai Hashimoto, Tomoyuki Fujisawa, Hideki Kusagaya, Takashi Matsui, Nao Inami, Kazuhiro Asada
Publikováno v:
Cancer Immunology, Immunotherapy
Background Lipids have immunomodulatory functions and the potential to affect cancer immunity. Methods The associations of pretreatment serum cholesterol and long-chain fatty acids with the objective response rate (ORR), progression-free survival (PF
Autor:
Mitsuyoshi Utsugi, Reiko Sakurai, Noriaki Sunaga, Akira Mogi, Yoshio Tomizawa, Tomohito Kuwako, Tomomi Masuda, T. Ishizuka, Kyoichi Kaira, Atsushi Takise, Yosuke Miura, Ryusei Saito, Kimihiro Shimizu, Kaori Seki, Koichi Minato, Masanobu Yamada, Hisao Imai, Shinichi Ishihara, Takeshi Hisada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point
Autor:
Radoslav Chekerov, Desislava Dimitrova, Jalid Sehouli, Mustafa Zelal Muallem, Ingo B. Runnebaum, Michael P. Lux, Hans Werner Tessen, Oliver Tome, Oumar Camara, Beate Rautenberg, Tanja Trarbach, Gerald Gitsch
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Objective In recurrent ovarian cancer (ROC), there is a high demand on effective therapies with a mild toxicity profile. Treosulfan is an alkylating agent approved as oral (p.o.) and intravenous (i.v.) formulation for the treatment of recurrent ovari